These data suggest that Cyclin D3–CDK6 supports survival via metabolism, and its inhibition can lead to tumor shrinkage, highlighting the impact of CDK4/6 balance on CDK4/6 inhibitor efficacy. This evidence concerns the gene CDK4 and neoplasm.